

**THOUGHT LEADERSHIP**

NEWS RELEASES    PUBLISHED: SEPTEMBER 30, 2022

**Service**Generic Drug / ANDA  
Litigation**Industry**

Life Sciences

**Professional**

**DON J. MIZERK**  
CHICAGO:  
312.526.1546  
[DON.MIZERK@  
HUSCHBLACKWELL.COM](mailto:DON.MIZERK@HUSCHBLACKWELL.COM)

## Husch Blackwell Named as Top ANDA Litigation Law Firm by Patexia

Husch Blackwell is pleased to announce that the firm has again been recognized by Patexia, the world's largest network for intellectual property professionals, in its ANDA Litigation Intelligence Report 2022 as being among the top 100 most active law firms handling Abbreviated New Drug Application (ANDA) litigation.

Patexia's study measured the performance and activity of stakeholder organizations, including attorneys, law firms, pharmaceutical companies and judges, evaluating more than 260 law firms and 1,857 attorneys over a five-year period ending in June 2022. The study analyzed more than 1,400 cases involving over 1,500 patents.

Husch Blackwell was ranked among the top 50 firms for its performance on behalf of defendants in ANDA litigation and among the top 100 firms for its performance on behalf of plaintiffs. Partner Don Mizerk garnered individual rankings among the most active ANDA attorneys on the defendant side. The firm also placed among the top 100 most active law firms representing generic drug makers as defendants and plaintiffs in ANDA litigation, with 13 cases appearing in the study.

Husch Blackwell's ANDA litigation team spans multiple offices and comprises 14 lawyers and two scientific advisors. The team has handled litigation involving blockbuster drug categories, including anticoagulants, antidepressants, H1 antagonists, and antiarrhythmic agents.